^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    p38 inhibitor

    Related drugs:
    19d
    Osteopontin Promotes Liver Echinococcus multilocularis Growth and Invasion via p38MAPK Pathway. (PubMed, Parasite Immunol)
    The mice in the anti-p38MAPK group and the anti-p38MAPK + LV-OPN-0423 group were then given SB202190 (this is an inhibitor of p38MAPK) for 4 weeks, and the mice in each group were injected with corresponding lentivirus diluent once a week for 8 weeks...The OPN level promoted the expression of p38MAPK and p-p38MAPK. These results suggested that OPN could regulate Em's growth and metastasis through the p38MAPK signalling pathway in host hepatocytes, providing evidence that OPN and p38MAPK may be novel molecular targets for treating alveolar echinococcosis.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1)
    |
    SB202190
    30d
    Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (clinicaltrials.gov)
    P1/2, N=70, Active, not recruiting, Dan Zandberg | Trial completion date: Oct 2025 --> Dec 2025
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • pexmetinib (ARRY-614)
    1m
    A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) (clinicaltrials.gov)
    P2, N=52, Recruiting, GEn1E Lifesciences | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    2ms
    A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, EIP Pharma Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, GEn1E Lifesciences
    New P1 trial
    4ms
    Promoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females. (PubMed, BMC Cancer)
    Promoting mitochondrial fusion via OPA1 induction improved cachectic outcomes in mice. Targeting OPA1providing provides a promising therapeutic approach for CC treatment.
    Journal
    |
    FOXO3 (Forkhead box O3) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    5ms
    Estrogen-mediated corneal collagen degradation in keratoconus. (PubMed, iScience)
    Our model showed that both corneal epithelium and fibroblasts synthesize their own estrogen, and β-estradiol treatment via p38 MAP kinase pathway regulates MMP2-mediated collagen fiber degradation. p38 MAP kinase inhibitor SB202190 significantly reduced β-estradiol-induced MMP activity and collagen breakdown, as well as cytokine regulation suggesting a potential therapeutic approach.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • MMP2 (Matrix metallopeptidase 2) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    SB202190
    5ms
    A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=25, Recruiting, EIP Pharma Inc | Trial completion date: Jan 2026 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    5ms
    RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=159, Completed, EIP Pharma Inc | Active, not recruiting --> Completed
    Trial completion
    5ms
    Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia (clinicaltrials.gov)
    P2, N=20, Recruiting, EIP Pharma Inc
    New P2 trial
    6ms
    Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells. (PubMed, Elife)
    We further validate that a specific p38-MK2 inhibitor significantly potentiates the efficacy of subclinical concentrations of MTA. In summary, our findings suggest that the p38-MK2 pathway presents a promising therapeutic target in combination with MTAs in cancer treatment.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9)
    7ms
    RESTORE: A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke (clinicaltrials.gov)
    P2, N=90, Recruiting, EIP Pharma Inc
    New P2 trial